|
Parameter*
|
CYC (n = 25)
|
MMF (n = 25)
|
|---|
|
Age at recruitment (years)
|
31.4 ± 6.4
|
28.4 ± 4.4
|
|
Age at diagnosis (years)
|
28.4 ± 6.1
|
24.1 ± 4.4
|
|
Duration of disease from diagnosis (years)
|
3 ± 2.9
|
4.3 ± 4
|
|
SLEDAI
|
7.2 ± 2.5
|
5.8 ± 3.4
|
|
Marital status
|
|
Unmarried
|
6 (24%)
|
8 (32%)
|
|
Completed family
|
13 (52%)
|
6 (24%)
|
|
Gestational history
|
|
Median number of successful pregnancies
|
1
|
1
|
|
Median number of abortions
|
0
|
0
|
|
Menstrual cycles at recruitment
|
|
Regular
|
24 (96%)
|
24 (96%)
|
|
Oligomenorrhoea
|
1 (4%)
|
1 (4%)
|
|
ANA positivity
|
25 (100%)
|
25 (100%)
|
|
dsDNA positivity
|
21 (84%)
|
23 (92%)
|
|
Hypocomplementaemia
|
17 (68%)
|
13 (52%)
|
|
Creatinine (mg/dl)
|
1.38 ± 0.92
|
0.93 ± 0.56
|
|
TSH (mIU/l)
|
3.37 ± 1.95
|
2.69 ± 2.24
|
|
Testosterone (nmol/l)
|
0.29 ± 0.35
|
0.47 ± 0.71
|
|
Prolactin (ng/ml)
|
18.26 ± 7.60
|
23.31 ± 21.02
|
|
Kidney biopsy class
|
|
Class II
|
1 (5%)
|
1 (4.5%)
|
|
Class III
|
2 (10%)
|
5 (23.7%)
|
|
Class IV
|
12 (60%)
|
6 (27.3%)
|
|
Class III + V
|
0
|
1 (4.5%)
|
|
Class IV + V
|
5 (25%)
|
2 (9%)
|
|
Class V
|
0
|
7 (32%)
|
- CYC cyclophosphamide, MMF mycophenolate mofetil, SLEDAI Systemic Lupus Erythematosus Disease Activity Index, ANA antinuclear antibodies, dsDNA anti-double-stranded deoxyribonucleic acid antibodies, TSH thyroid-stimulating hormone
- *Reported as mean ± SD or n (%)
